Proton Laboratories Inc., (PLBI.PK), through Regenobody S.A. ("Regenobody"), a Dominican Republic ("DR") company has been licensed by the DR government to investigate, experiment, treat and develop autologus stem cells for regenerating one's own cellular tissues. Regenobody has the exclusive rights in its territory to the RNL BIO Company Ltd. of Korean systems and equipment for the banking, manufacture and right to purchase stem cells from RNL-BIO for a period of 20 years. The license extends to all of the Caribean, Central and South America. RNL-BIO Company Ltd. of Korea is the holder of the world wide patents relating to the harvesting, cultivation and implantation of autologus and adipose tissue derived mesenchymal stem cells and the equipment necessary to utilize the patented process.
Regenobody is expected to commence it's stem cell therapy and treatmentst in the DR in early September, 2010 under the 20 year exclusive regional territory license from RNL-BIO mentioned previously.Many are positionining themselves between now and the opening of the DR facilities when stock prices should reflect the new and exciting services, treatments and thrapies that PLBI has to offer through it's Regenobody division.